Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.76 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.76 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Endomorphin 2 SCHEMBL29577635 | 1.00 | OPRM1 (0.76) | OPRM1OPRD1OPRK1 | |
| Endomorphin 2 SCHEMBL13252092 | 1.00 | OPRM1 (0.76) | OPRM1OPRD1OPRK1 | |
| Endomorphin 2 SCHEMBL22649436 | 1.00 | OPRM1 (0.76) | OPRM1OPRD1OPRK1 | |
| SCHEMBL38658663 | 0.96 | OPRM1 (0.78) | OPRM1OPRD1OPRK1 | |
| SCHEMBL31060785 | 0.94 | OPRM1 (0.69) | OPRM1OPRD1OPRK1 | |
| SCHEMBL29576785 | 0.94 | SLC6A2 (0.74) | OPRM1OPRD1OPRK1 | |
| SCHEMBL29577073 | 0.93 | OPRM1 (0.67) | OPRM1OPRD1OPRK1 | |
| Acetic Acid SCHEMBL11289266 | 0.93 | OPRM1 (0.69) | OPRM1OPRD1OPRK1 | |
| SCHEMBL30157193 | 0.92 | OPRM1 (0.73) | OPRM1OPRD1OPRK1 | |
| SCHEMBL23114234 | 0.91 | OPRM1 (0.67) | OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118063557-A | Hyaluronic acid modifier of cosmetic peptide and application thereof | 杭州湃肽生化科技有限公司 | 2024-05-24 | — | — | CN | claimed |
| CN-117964700-A | Novel transmembrane polypeptide with dual functions of easing pain and resisting anxiety | 中国人民解放军空军军医大学 | 2024-05-03 | — | — | CN | claimed |
| CN-117050145-A | Hyaluronic acid modifier of cosmetic peptide and application thereof | 杭州湃肽生化科技有限公司 | 2023-11-14 | — | — | CN | claimed |
| CN-117050146-A | Hyaluronic acid modified cosmetic peptide, preparation method and application thereof | 杭州湃肽生化科技有限公司 | 2023-11-14 | — | — | CN | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| EP-3795146-B1 | PAIN-RELIEVING AND ANTI-INFLAMMATORY COMPOSITION FOR LOCAL USE | AQMA ITALIA S P A (IT) | 2023-06-07 | — | — | EP | claimed |
| CN-114096330-B | Metal phase change compound and preparation method thereof | 维白奥锤有限公司 | 2023-04-04 | — | — | CN | claimed |
| US-20220401430-A1 | ALLOSTERIC MODULATORS OF THE MU OPIOID RECEPTOR | Chiromics, LLC | 2022-12-22 | — | — | US | claimed |
| US-11396453-B2 | Metal compound having phase transformation and method of preparing the same | WEBIOTREE CO.. LTD (KR) | 2022-07-26 | — | — | US | claimed |
| CN-122094704-A | Formulations for oral administration of active agents comprising a combination of acid-neutralizing polymer and non-polymeric material | — | 2026-05-26 | — | — | CN | disclosed |
| WO-2026099555-A1 | COSMETIC USE OF AN EXTRACT OF LYSIMACHIA CHRISTINAE | BASF BEAUTY CARE SOLUTIONS FRANCE SAS (FR) | 2026-05-15 | — | — | WO | disclosed |
| US-20260124143-A1 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | OREXO AB (SE) | 2026-05-07 | — | — | US | disclosed |
| US-12617790-B2 | Mitragynine analogs and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260115162-A1 | COMPOSITION OR ASSOCIATION OF COMPOUNDS PREFERABLY FOR USE IN THE TREATMENT OF NERVOUS DISEASES IN PARTICULAR NEURODEGENERATIVE DISEASES, METHOD FOR THE PREPARATION OF SUCH COMPOSITION OR ASSOCIATION OF COMPOUNDS AND USES THEREOF | PHARMACEUTICA SAN MARCO S R L (IT) | 2026-04-30 | — | — | US | disclosed |
| EP-3962455-A1 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | Orexo AB (SE) | 2022-03-09 | — | — | EP | disclosed |
| EP-3962928-A1 | METHOD FOR TREATING OPIOID USE DISORDER | The Administrators of The Tulane Educational Fund (US) | 2022-03-09 | — | — | EP | disclosed |
| EP-3962510-A1 | NOVEL SELECTIVE ACKR3 MODULATORS AND USES THEREOF | Luxembourg Institute Of Health (LIH) (LU) | 2022-03-09 | — | — | EP | disclosed |
| CN-114126615-A | Opioid receptor antagonist prodrugs | 尼萨姆实验室公司 | 2022-03-01 | — | — | CN | disclosed |
| US-20220056075-A1 | METHOD FOR TREATING OPIOID USE DISORDER | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2022-02-24 | — | — | US | disclosed |
| US-11246873-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617790-B2 | Mitragynine analogs and uses thereof | OPRM1, OPRK1, OPRL1 | OPRM1 1/4885OPRD1 4/4885OPRK1 2/4885 |
| US-20220401430-A1 | ALLOSTERIC MODULATORS OF THE MU OPIOID RECEPTOR | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
| US-20260124143-A1 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | SLC5A1, SLC5A2, GLP1R | OPRM1 2154/4885OPRD1 1267/4885OPRK1 2591/4885 |
| US-20260115162-A1 | COMPOSITION OR ASSOCIATION OF COMPOUNDS PREFERABLY FOR USE IN THE TREATMENT OF NERVOUS DISEASES IN PARTICULAR NEURODEGENERATIVE DISEASES, METHOD FOR THE PREPARATION OF SUCH COMPOSITION OR ASSOCIATION OF COMPOUNDS AND USES THEREOF | HBZ, ALOX12, SNCA | OPRM1 441/4885OPRD1 406/4885OPRK1 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.